Liver cirrhosis

May 10, 2017May 10, 2017

Novartis Exercises Option to Develop and Market Conatus’ Emricasan to Treat NASH

Liver cirrhosis, News, Non-alcoholic fatty liver disease, Non-alcoholic steatohepatitis

Novartis is exercising an option to become the exclusive developer and global marketer of Conatus Pharmaceuticals‘ liver-disease treatment emricasan. Under the agreement, signed in December 2016, Novartis will obtain the license ... Read more

May 8, 2017

New ‘Liver Line’ Online Community to Share Updates on Health, Research, Treatments

Alcoholic liver disease, Hepatitis, Liver cancer, Liver cirrhosis, News, Non-alcoholic fatty liver disease, Non-alcoholic steatohepatitis

A new online community, called Liver Line and sponsored by Galectin Therapeutics, offers the latest information on liver health and research into liver diseases. On Liver Line, patients and the community can learn ... Read more

April 17, 2017April 19, 2017

Galectin Plans to Present Data from Phase 2 NASH Cirrhosis Trial by Year’s End

Liver cirrhosis, News, Non-alcoholic steatohepatitis

Galectin Therapeutics’s lead drug GR-MD-02 may be a promising therapeutic approach to treat fibrosis in fatty liver disease — or non-alcoholic steatohepatitis (NASH) — based on results from a Phase 1 study. The company is ... Read more

April 11, 2017April 11, 2017

Conatus Discusses Its Liver Disease Therapy Emricasan at Two New York Events

Liver cirrhosis, News, Non-alcoholic fatty liver disease, Non-alcoholic steatohepatitis

Conatus Pharmaceuticals updated participants at two New York medical conferences this month on its efforts to develop emricasan, which has been shown to improve manifestations of chronic kidney disease. The San Diego-based ... Read more

March 16, 2017April 5, 2017

Coffee Intake May Reduce Risk of Chronic Liver Disease, Study Says

Alcoholic liver disease, Hepatitis, Liver cirrhosis, News, Non-alcoholic fatty liver disease

Drinking coffee may reduce the risk of chronic liver disease, especially in patients with other conditions affecting the liver, including non-alcoholic fatty liver disease, according to a new study. But ... Read more